Several studies shown that significant upregulation of EphA1, EphA2, EphA3, EphA4, EphB2, and EphB4 occurs throughout CRC progression [7, 8], and EphA2 has been shown to be a marker for advanced disease and a poor prognosis and is a critical therapeutic target [9]. This evidence concerns the gene EPHB2 and colorectal carcinoma.